Form PTO-1449

at of Commerce ATTY. DOCKET NO.

S08 Rec'd PCT/PTO

1 4 MAY 2001

Sheet 1 of 1.

	at of Commerc
Patent and	l Ademark Office

IVD 1087

Cori**0.9** / 831 720 PCT/FR99/02761

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT

CASELLAS, Pierre and DEROCQ, Jean-Marie

(Use several sheets if necessary)

FILING DATE Herewith

GROUP Unknown

## U.S. PATENT DOCUMENTS

Exammer kutial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
,						
	 					:
					·- · · · · ·	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class Subclass		Translation	
						Yes	No
1	1			i		1	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BTO	Levy, A Psychosomatic Approach to the Management Of Recalcitrant Dermatoses, 4(6), Nov. 1963, 334-337.
	Ormfa et al., Ricerche preliminari clinico-psicologiche su di un nuovo derivato benzodiazepinico (Nobrium) in dermatologia, 45(5), May 1970, 325-339.
	Carayon et al., Involvement of Peripheral Benzodiazepine Receptors in the Protection of Hematopoietic Cells Against Oxygen Radical Damage, 87(8), April 1996, 3170-3178.
BIE	Boh et al., Role of Reactive Oxygen Species in Dermatologic Diseases, 14(4), July 1996, 343-352.
EXAMINER	DATE CONSIDERED 7 (17 /°)

conformance and not considered. Include copyof this form with next communication to applicant.

Paper #3